Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability

Amyotrophic Lateral Sclerosis

Volumn 10, Issue 5-6, 2009, Pages 410-415

  Lauria, Giuseppe ^a   Campanella, Angela ^a   Filippini, Graziella ^b   Martini, Alfredo ^b   Penza, Paola ^a   Maggi, Lorenzo ^a   Antozzi, Carlo ^a   Ciano, Claudia ^b   Beretta, Pinuccia ^b   Caldiroli, Dario ^b   Ghelma, Filippo ^c   Ferrara, Giovanni ^d   Ghezzi, Pietro ^d   Mantegazza, Renato ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b IRCCS Foundation   (United States)

^c General Surgery Unit   (United States)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Clinical trial; Erythropoietin; Survival; Therapy

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE; FEMALE; FLU LIKE SYNDROME; HEMATOCRIT; HUMAN; HYPERTENSION; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; SCREENING TEST; SURVIVAL RATE; THROMBOCYTOSIS; TRACHEOTOMY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70450175252     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960902995246     Document Type: Article

References (15)

1. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (New York, NY). 2004;305: 239-42.
2. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine (Cambridge, Mass). 2002;8:495-505.
3. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry. 2007;12:206-20.
4. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577-88. (Pubitemid 47511714)
5. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641-7.
6. Keswani SC, Buldanlioglu U, Fischer A, Reed N, Polley M, Liang H, et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Annals of Neurology. 2004;56:815-26.
7. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:10526-31.
8. Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Experimental Neurology. 2007;204:260-3.
9. Grignaschi G, Zennaro E, Tortarolo M, Calvaresi N, Bendotti C. Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotroph Lateral Scler. 2007;8:31-5.
10. Mennini T, de Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, et al. Non-haematopoietic erythropoietin derivatives prevent motor neuron degeneration in vitro and in vivo. Molecular Medicine (Cambridge, Mass). 2006;12:153-60.
11. Brettschneider J, Widl K, Schattauer D, Ludolph AC, Tumani H. Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neuroscience Letters. 2007; 416:257-60.
12. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron. 2004;96: 88-95.
13. McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754-62.
14. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses in healthy subjects. Clin Pharmacol Ther. 1998;64:412-23.
15. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:823-8.